Drug Profile

Research programme: HBV cccDNA epigenetic modifiers - Arbutus Biopharma

Alternative Names: cccDNA epigenetic modifiers - Arbutus Biopharma; Covalently closed circular DNA epigenetic modifiers - Arbutus Biopharma

Latest Information Update: 28 Dec 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
Developer Arbutus Biopharma; Baruch S. Blumberg Institute
Class Antivirals; Small molecules
Mechanism of Action Genetic transcription modulators; Hepatitis B virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2018 No recent reports of development identified for research development in Hepatitis-B in USA (PO)
30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
03 Aug 2015 Tekmira Pharmaceuticals is now called Arbutus Biopharma

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com